Prognostic value of cardiac sympathetic nerve imaging using long-term follow-up data: Ischemic vs. non-ischemic heart failure etiology

Circulation Journal

Volumn 80, Issue 2, 2016, Pages 435-441

  Matsuo, Shinro ^a   Nakajima, Kenichi ^a   Nakata, Tomoaki ^b  

^a KANAZAWA UNIVERSITY HOSPITAL   (Japan)

^b HAKODATE GORYOUKAKU HOSPITAL   (Japan)

Author keywords

123I meta iodobenzylguanidine; Heart failure; Heart to mediastinum ratio; Ischemic origin; Prognosis

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123; (3 IODOBENZYL)GUANIDINE;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; CARDIAC IMAGING; CARDIOMYOPATHY; ECHOCARDIOGRAPHY; FEMALE; FOLLOW UP; GATED SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY; HEART DEATH; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MORTALITY; OUTCOME ASSESSMENT; PROGNOSIS; PROSPECTIVE STUDY; ADRENERGIC SYSTEM; CLINICAL TRIAL; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; HEART MUSCLE ISCHEMIA; MULTICENTER STUDY; NEUROIMAGING; PATHOLOGY; PATHOPHYSIOLOGY; SURVIVAL RATE;

3-IODOBENZYLGUANIDINE; AGED; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL ISCHEMIA; NEUROIMAGING; PROSPECTIVE STUDIES; SURVIVAL RATE; SYMPATHETIC NERVOUS SYSTEM;

EID: 84955457910     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-15-0952     Document Type: Article

References (45)

1. Carrio I. Cardiac neurotransmission imaging. J Nucl Med 2001; 42: 1062–1076.
2. Jacobson AF, Senior R, Cerqueira MD, Wong ND, Thomas GS, Lopez VA, et al. Myocardial iodine-123 meta-iodobenzylguanidine imaging and cardiac events in heart failure: Results of the prospective ADMIRE-HF (AdreView Myocardial Imaging for Risk Evaluation in Heart Failure) study. J Am Coll Cardiol 2010; 55: 2212–2221.
3. Verschure DO, Veltman CE, Manrique A, Somsen GA, Koutelou M, Katsikis A, et al. For what endpoint does myocardial 123I-MIBG scintigraphy have the greatest prognostic value in patients with chronic heart failure?: Results of a pooled individual patient data meta-analysis. Eur Heart J Cardiovasc Imaging 2014; 15: 996–1003.
4. Nakata T, Nakajima K, Yamashina S, Yamada T, Momose M, Kasama S, et al. A pooled analysis of multicenter cohort studies of (123)I-mIBG imaging of sympathetic innervation for assessment of long-term prognosis in heart failure. JACC Cardiovasc Imaging 2013; 6: 772–784.
5. Nakajima K, Nakata T, Yamada T, Yamashina S, Momose M, Kasama S, et al. A prediction model for 5-year cardiac mortality in patients with chronic heart failure using 123I-metaiodobenzylguanidine imaging. Eur J Nucl Med Mol Imaging 2014; 41: 1673–1683.
6. Nishimura T, Nakajima K, Kusuoka H, Yamashina A, Nishimura S. Prognostic study of risk stratification among Japanese patients with ischemic heart disease using gated myocardial perfusion SPECT: J-ACCESS study. Eur J Nucl Med Mol Imaging 2008; 35: 319–328.
7. Matsuo S, Nakajima K, Horie M, Nakae I, Nishimura T; J-ACCESS Investigators. Prognostic value of normal stress myocardial perfusion imaging in Japanese population. Circ J 2008; 72: 611–617.
8. Matsuo S, Nakajima K, Yamasaki Y, Kashiwagi A, Nishimura T. Prognostic value of normal stress myocardial perfusion imaging and ventricular function in Japanese asymptomatic patients with type 2 diabetes: A study based on the J-ACCESS-2 database. Circ J 2010; 74: 1916–1921.
9. Kasama S, Toyama T, Kumakura H, Takayama Y, Ichikawa S, Suzuki T, et al. Spironolactone improves cardiac sympathetic nerve activity and symptoms in patients with congestive heart failure. J Nucl Med 2002; 43: 1279–1285.
10. Momose M, Kobayashi H, Iguchi N, Matsuda N, Sakomura Y, Kasanuki H, et al. Comparison of parameters of 123I-MIBG scintigraphy for predicting prognosis in patients with dilated cardiomyopathy. Nucl Med Commun 1999; 20: 529–535.
11. Nakata T, Miyamoto K, Doi A, Sasao H, Wakabayashi T, Kobayashi H, et al. Cardiac death prediction and impaired cardiac sympathetic innervation assessed by MIBG in patients with failing and nonfailing hearts. J Nucl Cardiol 1998; 5: 579–590.
12. Matsuo S, Nakamura Y, Matsumoto T, Nakae I, Takada M, Murata K, et al. Prognostic value of iodine-123 metaiodobenzylguanidine imaging in patients with heart failure. Exp Clin Cardiol 2003; 8: 95–98.
13. Agostini D, Verberne HJ, Burchert W, Knuuti J, Povinec P, Sambuceti G, et al. I-123-mIBG myocardial imaging for assessment of risk for a major cardiac event in heart failurepatients: Insights from a retrospective European multicenter study. Eur J Nucl Med Mol Imaging 2008; 35: 535–546.
14. Verberne HJ, Brewster LM, Somsen GA, van Eck-Smit BL. Prognostic value of myocardial 123I-metaiodobenzylguanidine (MIBG) parameters in patients with heart failure: A systematic review. Eur Heart J 2008; 29: 1147–1159.
15. Matsumoto N, Hirayama A. Current Japanese Ministry of Health, Labor, and Welfare approval of cardiac single photon emission computed tomography. Ann Nucl Cardiol 2015; 1: 108–109.
16. Matsuo S, Nakajima K. Assessment of cardiac sympathetic nerve function using 123I-meta-iodobenzylguanidine scintigraphy: Technical aspects and standardization. Ann Nucl Cardiol 2015; 1: 27–34.
17. Fallavollita JA, Heavey BM, Luisi AJ Jr., Michalek SM, Baldwa S, Mashtare TL Jr., et al. Regional myocardial sympathetic denervation predicts the risk of sudden cardiac arrest in ischemic cardiomyopathy. J Am Coll Cardiol 2014; 63: 141–149.
18. Boogers MJ, Borleffs CJ, Henneman MM, van Bommel RJ, van Ramshorst J, Boersma E, et al. Cardiac sympathetic denervation assessed with 123-iodine metaiodobenzylguanidine imaging predicts ventricular arrhythmias in implantable cardioverter-defibrillator patients. J Am Coll Cardiol 2010; 55: 2769–2777.
19. Nakajo M, Shapiro B, Copp J, Kalff V, Gross MD, Sisson JC, et al. The normal and abnormal distribution of the adrenomedullary imaging agent m-[I-131]iodobenzylguanidine (I-131 MIBG) in man: Evaluation by scintigraphy. J Nucl Med 1983; 24: 672–682.
20. Matsunari I, Schricke U, Bengel FM, Haase HU, Barthel P, Schmidt G, et al. Extent of cardiac sympathetic neuronal damage is determined by the area of ischemia in patients with acute coronary syndromes. Circulation 2000; 101: 2579–2585.
21. Matsuo S, Takahashi M, Nakamura Y, Kinoshita M. Evaluation of cardiac sympathetic innervation with iodine-123-metaiodobenzylguanidine imaging in silent myocardial ischemia. J Nucl Med 1996; 37: 712–717.
22. Kuwabara Y, Tamaki N, Nakata T, Yamashina S, Yamazaki J. Determination of the survival rate in patients with congestive heart failure stratified by 123I-MIBG imaging: A meta-analysis from the studies performed in Japan. Ann Nucl Med 2011; 25: 101–107.
23. Nakata T, Hashimoto A, Wakabayashi T, Kusuoka H, Nishimura T. Prediction of new-onset refractory congestive heart failure using gated myocardial perfusion SPECT imaging in patients with known or suspected coronary artery disease subanalysis of the J-ACCESS database. JACC Cardiovasc Imaging 2009; 2: 1393–1400.
24. Nakadate T, Nozawa T, Matsuki A, Nonomura M, Igarashi N, Igawa A, et al. Brief episode of myocardial ischemia before prolonged ischemia attenuates cardiac sympathetic nerve injury. Circ J 2006; 70: 919–925.
25. Minamisawa M, Izawa A, Motoki H, Kashima Y, Hioki H, Abe N, et al. Prognostic significance of neuroadrenergic dysfunction for cardiovascular events in patients with acute myocardial infarction. Circ J 2015; 79: 2238–2245.
26. Yamazaki J, Muto H, Kabano T, Yamashina S, Nanjo S, Inoue A. Evaluation of beta-blocker therapy in patients with dilated cardiomyopathy: Clinical meaning of iodine 123-metaiodobenzylguanidine myocardial single-photon emission computed tomography. Am Heart J 2001; 141: 645–652.
27. Matsuo S, Nakamura Y, Tsutamoto T, Kinoshita M. Impairments of myocardial sympathetic activity may reflect the progression of myocardial damage or dysfunction in hypertrophic cardiomyopathy. J Nucl Cardiol 2002; 9: 407–412.
28. Wakabayashi T, Nakata T, Hashimoto A, Yuda S, Tsuchihashi K, Travin MI, et al. Assessment of underlying etiology and cardiac sympathetic innervation to identify patients at high risk of cardiac death. J Nucl Med 2001; 42: 1757–1767.
29. Yamada T, Shimonagata T, Fukunami M, Kumagai K, Ogita H, Hirata A, et al. Comparison of the prognostic value of cardiac iodine-123 metaiodobenzylguanidine imaging and heart rate variability in patients with chronic heart failure: A prospective study. J Am Coll Cardiol 2003; 41: 231–238.
30. Ohshima S, Isobe S, Hayashi D, Abe S, Kato K, Murohara T. Myocardial 123I-MIBG scintigraphy predicts an impairment in myocardial functional reserve during dobutamine stress in patients with idiopathic dilated cardiomyopathy. Eur J Nucl Med Mol Imaging 2013; 40: 262–270.
31. Matsuo S, Nakae I, Tsutamoto T, Okamoto N, Horie M. A novel clinical indicator using Tc-99 m sestamibi for evaluating cardiac mitochondrial function in patients with cardiomyopathies. J Nucl Cardiol 2007; 14: 215–220.
32. Kuramoto Y, Yamada T, Tamaki S, Okuyama Y, Morita T, Furukawa Y, et al. Usefulness of cardiac iodine-123 meta-iodobenzylguanidine imaging to improve prognostic power of Seattle heart failure model in patients with chronic heart failure. Am J Cardiol 2011; 107: 1185–1190.
33. Akashi YJ, Nakazawa K, Sakakibara M, Miyake F, Musha H, Sasaka K. 123I-MIBG myocardial scintigraphy in patients with “takotsubo” cardiomyopathy. J Nucl Med 2004; 45: 1121–1127.
34. Tamaki S, Yamada T, Okuyama Y, Morita T, Sanada S, Tsukamoto Y, et al. Cardiac iodine-123 metaiodobenzylguanidine imaging predicts sudden cardiac death independently of left ventricular ejection fraction in patients with chronic heart failure and left ventricular systolic dysfunction: Results from a comparative study with signalaveraged electrocardiogram, heart rate variability, and QT dispersion. J Am Coll Cardiol 2009; 53: 426–435.
35. Gimelli A, Liga R, Genovesi D, Giorgetti A, Kusch A, Marzullo P. Association between left ventricular regional sympathetic denervation and mechanical dyssynchrony in phase analysis: A cardiac CZT study. Eur J Nucl Med Mol Imaging 2014; 41: 946–955.
36. Sugiura M, Yamamoto K, Takeda Y, Takeda Y, Dohmori T, Ogata M, et al. The relationship between variables of 123-I-metaiodobenzylguanidine cardiac imaging and clinical status of the patients with diastolic heart failure. Int J Cardiol 2006; 113: 223–228.
37. Tanaka H, Tatsumi K, Fujiwara S, Tsuji T, Kaneko A, Ryo K, et al. Effect of left ventricular dyssynchrony on cardiac sympathetic activity in heart failure patients with wide QRS duration. Circ J 2012; 76: 382–389.
38. Nagahara D, Nakata T, Hashimoto A, Wakabayashi T, Kyuma M, Noda R, et al. Predicting the need for an implantable cardioverter defibrillator using cardiac metaiodobenzylguanidine activity together with plasma natriuretic peptide concentration or left ventricular function. J Nucl Med 2008; 49: 225–233.
39. Nishisato K, Hashimoto A, Nakata T, Doi T, Yamamoto H, Nagahara D, et al. Impaired cardiac sympathetic innervation and myocardial perfusion are related to lethal arrhythmia: Quantification of cardiac tracers in patients with ICDs. J Nucl Med 2010; 51: 1241–1249.
40. Matsuo S, Nakajima K, Okuda K, Kawano M, Ishikawa T, Hosoya T, et al. Standardization of the heart-to-mediastinum ratio of iodine- 123-labeled-meta-iodobenzylguanidine uptake using dual energy window method: Feasibility of correction from different cameracollimator combinations. Eur J Nucl Med Mol Imaging 2009; 36: 560–566.
41. Matsuo S, Nakae I, Masuda D, Matsumoto T, Horie M. Dilated cardiomyopathy relieved as a result of beta-blocker therapy: A case report–key points in assessment of prognosis based on MIBG myocardial scintigraphy and BNP levels. Ann Nucl Med 2005; 19: 243–246.
42. Matsuo S, Nakajima K, Yamashina S, Sakata K, Momose M, Hashimoto J, et al. Characterization of Japanese standards for myocardial sympathetic and metabolic imaging in comparison with perfusion imaging. Ann Nucl Med 2009; 23: 517–522.
43. Yoshinaga K, Tomiyama Y, Manabe O, Kasai K, Katoh C, Magota K, et al. Prone-position acquisition of myocardial (123)I-metaiodobenzylguanidine (MIBG) SPECT reveals regional uptake similar to that found using (11)C-hydroxyephedrine PET/CT. Ann Nucl Med 2014; 28: 761–769.
44. Sood N, Al Badarin F, Parker M, Pullatt R, Jacobson AF, Bateman TM, et al. Resting perfusion MPI-SPECT combined with cardiac 123I-mIBG sympathetic innervation imaging improves prediction of arrhythmic events in non-ischemic cardiomyopathy patients: Substudy from the ADMIRE-HF trial. J Nucl Cardiol 2013; 20: 813–820.
45. Ushigome R, Sakata Y, Nochioka K, Miyata S, Miura M, Tadaki S, et al. Improved long-term prognosis of dilated cardiomyopathy with implementation of evidenced-based medication: Report from the CHART studies. Circ J 2015; 79: 1332–1341.